DUBLIN

都柏林

,

，

June 25, 2026

2026年6月25日

/PRNewswire/ -- Davion Healthcare Plc ('Davion' or the 'Company'), a next-generation digital healthcare company developing non-invasive remote health monitoring solutions for the early identification of medical anomalies associated with serious health conditions, today announces that it has entered into a share purchase agreement to acquire 100% of Humaskan Ltd ('Humaskan'), a medical technology company, focused on proprietary healthcare products and intellectual property.  .

/美通社/ -- 达维昂医疗保健有限公司（“Davion”或“公司”）是一家下一代数字医疗企业，致力于开发非侵入式远程健康监测解决方案，以早期识别与严重健康状况相关的医学异常。该公司今日宣布，已签署一份股份购买协议，将收购医疗科技公司Humaskan Ltd（“Humaskan”）100%的股权。Humaskan专注于专有医疗产品和知识产权。

In addition, the Company announces the proposed establishment of a wholly owned United Kingdom subsidiary, Davion Healthcare Finance Ltd, which is intended to support the Group's planned acquisition and expansion strategy across the United States and Europe.

此外，公司宣布拟设立一家全资子公司Davion Healthcare Finance Ltd（英国），旨在支持集团在美国和欧洲的计划收购及扩张战略。

As previously announced, Davion continues to execute its strategy of building a broader healthcare platform through a combination of product development, commercial infrastructure, strategic financing capability and selective acquisitions. The proposed acquisition of Humaskan follows the recently announced acquisition of Solar Medical and Chemical Limited, which is intended to establish Davion's principal commercial and distribution platform in the United Kingdom..

正如此前所宣布，Davion 继续通过产品开发、商业基础设施、战略融资能力以及选择性收购相结合的方式，执行其构建更广泛医疗健康平台的战略。拟议中对 Humaskan 的收购紧随近期宣布的对 Solar Medical and Chemical Limited 的收购，后者旨在建立 Davion 在英国的主要商业和分销平台。

Transaction Summary – Humaskan Acquisition

交易摘要 – Humaskan 收购案

The proposed acquisition comprises the purchase of 100% of the issued share capital of Humaskan for total consideration of $60 million.

拟议的收购包括以6,000万美元的总对价购买Humaskan已发行股本的100%。

The consideration is proposed to be satisfied through:

对价拟通过以下方式支付：

$10 million in cash consideration; and

1,000万美元现金对价；以及

$50 million through the issue of ordinary shares in Davion.

通过发行Davion的普通股筹集5,000万美元。

The equity consideration is proposed to be issued at a reference price of $13.00 per share and would be subject to a nine-month lock-up arrangement and orderly market disposal provisions thereafter.

拟以每股13.00美元的参考价格发行股权对价，并须遵守九个月的锁定期安排及此后的有序市场处置规定。

Strategic Financing Initiative – Davion Healthcare Finance Ltd

战略融资计划——达维安医疗金融有限公司

To support the Company's planned acquisition programme and provide additional acquisition funding flexibility, Davion intends to establish Davion Healthcare Finance Ltd as a wholly owned United Kingdom subsidiary.

为支持公司的计划收购项目并提供额外的收购资金灵活性，Davion 拟设立 Davion Healthcare Finance Ltd 作为其全资拥有的英国子公司。

Subject to market conditions, regulatory processes, final approvals and completion of transaction documentation, Davion Healthcare Finance Ltd anticipates establishing a corporate bond programme of up to £100 million.

在市场条件、监管流程、最终审批以及交易文件完成的前提下，Davion Healthcare Finance Ltd 预计将设立一个规模高达1亿英镑的公司债券计划。

The proposed programme is expected to comprise three intended series:

拟议的方案预计包括三个计划中的系列：

Series 1 – up to £30 million.

第一系列——最高3000万英镑。

Series 2 – up to £30 million.

第二系列——高达3000万英镑。

Series 3 – up to £40 million.

系列3 – 高达4000万英镑。

The Company currently expects the bonds to carry an indicative fixed coupon of 10.5% per annum and an intended maturity profile of five years.

本公司目前预计，该债券的指示性固定票面利率为每年10.5%，目标期限为五年。

The Company currently intends that the bonds will be offered exclusively to professional, sophisticated and institutional investors and will not be made available to retail investors.

本公司目前计划，该等债券将仅向专业、成熟及机构投资者发售，而不向零售投资者提供。

Subject to final approvals and market conditions, the Company currently expects each bond series to apply for admission to trading on the Vienna Stock Exchange MTF platform and currently anticipates launch activities commencing in August 2026.

在获得最终批准并视市场状况而定，公司目前预计各系列债券将申请在维也纳证券交易所多边交易设施（MTF）平台上市交易，并目前预期发行活动将于2026年8月启动。

The Company intends that proceeds raised under the proposed programme will be directed toward the Group's acquisition programme across the United States and Europe.

公司拟将拟议计划所筹集的资金用于集团在美国和欧洲的收购计划。

The Company currently expects that any bond programme would be structured through Davion Healthcare Finance Ltd as issuer, and that acquisition assets funded through the programme may form part of the overall Group structure while being subject to dedicated security arrangements in support of the financing programme..

本公司目前预期，任何债券计划将通过Davion Healthcare Finance Ltd作为发行人进行构建，并且通过该计划融资的收购资产可能在受专门担保安排支持的同时，成为集团整体结构的一部分。

Reasons for Acquisition and Financing Strategy

收购原因及融资策略

The Board believes the proposed acquisition of Humaskan, together with the proposed financing structure, has the potential to accelerate Davion's broader healthcare platform strategy through the addition of complementary intellectual property, products and commercial opportunities while supporting disciplined capital deployment..

董事会认为，拟议收购Humaskan公司以及配套的融资结构，有望通过补充知识产权、产品和商业机会，加速Davion更广泛的医疗平台战略，同时支持审慎的资本配置。

The combined strategy is intended to:

组合策略旨在：

Broaden Davion's healthcare technology and intellectual property portfolio;

扩大大卫医疗科技公司的医疗保健技术和知识产权组合；

Expand the Group's product development and manufacturing capabilities;

拓展集团的产品开发与制造能力；

Create additional routes for revenue growth and commercial expansion;

开辟更多航线，以促进收入增长和商业扩张；

Support acquisition opportunities across target healthcare sectors in Europe and the United States; and

支持在欧洲和美国目标医疗保健领域的收购机会；以及

Strengthen the scalability and flexibility of the Group's healthcare platform.

加强集团医疗健康平台的可扩展性和灵活性。

Completion of the Humaskan acquisition and implementation of any financing programme remain subject to completion of definitive documentation, regulatory considerations, and satisfaction of customary conditions.

Humaskan收购的完成及任何融资计划的实施，仍须以最终文件的签署、监管审批以及满足惯例条件为前提。

Jack Kaye, CEO of Davion Healthcare Plc, commented:

Davion Healthcare Plc 首席执行官 Jack Kaye 评论道：

'The proposed acquisition of Humaskan and the intended establishment of Davion Healthcare Finance Ltd reflect our strategy of building a broader and more scalable healthcare platform.

拟议收购Humaskan公司以及计划设立Davion Healthcare Finance Ltd，反映了我们构建更广泛、更具可扩展性的医疗健康平台的战略。

'We believe combining proprietary technologies, commercial capability, targeted acquisitions and access to long-term institutional capital has the potential to create a flexible foundation for future growth.

我们相信，将专有技术、商业能力、针对性收购以及获取长期机构资本的渠道相结合，有望为未来增长奠定灵活的基础。

'Our intention is to create a financing platform capable of supporting disciplined acquisition activity whilst maintaining a long-term approach to value creation.'

“我们的目标是创建一个能够支持有序收购活动的融资平台，同时坚持长期价值创造的理念。”

The Company will provide further updates regarding the proposed acquisition, financing programme and anticipated implementation timetable in due course.

本公司将在适当时候就拟议收购、融资计划及预期实施时间表提供进一步更新。

Contacts

联系人

Media Enquiries:

媒体咨询：

[email protected]

[email protected]

For more information please visit:

欲了解更多信息，请访问：

www.davionhealthcare.com

www.davionhealthcare.com

FORWARD LOOKING STATEMENTS

前瞻性陈述

This announcement contains forward-looking statements within the meaning of the 'safe harbor' provisions of the U.S. Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, those identified by words such as 'believes,' 'will,' 'expects,' 'anticipates,' 'estimates,' 'intends,' 'plans,' 'targets,' 'projects' and similar expressions.

本公告包含1995年美国《私人证券诉讼改革法》“安全港”条款所定义的前瞻性陈述。此类陈述包括但不限于使用“相信”、“将”、“预期”、“预计”、“估计”、“打算”、“计划”、“目标”、“规划”等词语及类似表述所识别的陈述。

The statements in this release are based upon the current beliefs and expectations of our company's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in these forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, the results of product evaluations, studies, regulatory reviews and commercial adoption and/or other studies, clinical trials, the challenges inherent in new product development initiatives, the impact of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future, changes in government policy and/or regulation, potential litigation by or against us, any governmental review of our products or practices, and other risks discussed from time to time in our filings with the Securities and Exchange Commission.

本新闻稿中的陈述基于本公司管理层当前的信念和预期，并受到重大风险和不确定性的影响。实际结果可能与这些前瞻性陈述中列出的结果存在差异。诸多因素可能导致或促成此类差异，包括但不限于：产品评估、研究、监管审查及商业化采纳和/或其他研究的结果；临床试验；新产品开发举措中固有的挑战；任何竞争性产品的冲击；我们许可和保护知识产权的能力；未来筹集额外资本的能力；政府政策和/或法规的变化；针对我们或由我们发起的潜在诉讼；政府对我们产品或实践的任何审查；以及我们在向美国证券交易委员会提交的文件中不时讨论的其他风险。

We undertake no obligation to update any forward-looking statements, or any information contained in this press release or in other public disclosures, at any time. Finally, the investing public is reminded that only announcements or information about Davion Healthcare Plc disseminated by the Company and bearing its name are considered official..

我们不承担任何义务，在任何时候更新任何前瞻性陈述，或本新闻稿或其他公开披露中包含的任何信息。最后，提醒广大投资者，只有由本公司发布并冠以本公司名称的关于 Davion Healthcare Plc 的公告或信息才被视为官方信息。

SOURCE DAVION HEALTHCARE PLC

来源：Davion Healthcare PLC

21

二十一

%

百分比

more press release views with

更多新闻稿浏览量，通过

Request a Demo

申请演示